JP2019527196A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527196A5
JP2019527196A5 JP2018565257A JP2018565257A JP2019527196A5 JP 2019527196 A5 JP2019527196 A5 JP 2019527196A5 JP 2018565257 A JP2018565257 A JP 2018565257A JP 2018565257 A JP2018565257 A JP 2018565257A JP 2019527196 A5 JP2019527196 A5 JP 2019527196A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
aryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565257A
Other languages
English (en)
Japanese (ja)
Other versions
JP7060245B2 (ja
JP2019527196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039787 external-priority patent/WO2018005662A1/en
Publication of JP2019527196A publication Critical patent/JP2019527196A/ja
Publication of JP2019527196A5 publication Critical patent/JP2019527196A5/ja
Application granted granted Critical
Publication of JP7060245B2 publication Critical patent/JP7060245B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565257A 2016-06-30 2017-06-28 ボロン酸誘導体およびその治療的使用 Active JP7060245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357165P 2016-06-30 2016-06-30
US62/357,165 2016-06-30
PCT/US2017/039787 WO2018005662A1 (en) 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2019527196A JP2019527196A (ja) 2019-09-26
JP2019527196A5 true JP2019527196A5 (cg-RX-API-DMAC7.html) 2020-08-06
JP7060245B2 JP7060245B2 (ja) 2022-04-26

Family

ID=60785544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565257A Active JP7060245B2 (ja) 2016-06-30 2017-06-28 ボロン酸誘導体およびその治療的使用

Country Status (23)

Country Link
US (4) US10294249B2 (cg-RX-API-DMAC7.html)
EP (1) EP3478693B1 (cg-RX-API-DMAC7.html)
JP (1) JP7060245B2 (cg-RX-API-DMAC7.html)
KR (1) KR102403296B1 (cg-RX-API-DMAC7.html)
CN (1) CN109415386B (cg-RX-API-DMAC7.html)
AU (1) AU2017290060B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018077015B1 (cg-RX-API-DMAC7.html)
CA (1) CA3026582A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003681A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018013978A2 (cg-RX-API-DMAC7.html)
DK (1) DK3478693T3 (cg-RX-API-DMAC7.html)
ES (1) ES2894251T3 (cg-RX-API-DMAC7.html)
IL (1) IL263450B (cg-RX-API-DMAC7.html)
MX (1) MX389349B (cg-RX-API-DMAC7.html)
MY (1) MY196909A (cg-RX-API-DMAC7.html)
PH (1) PH12018502747A1 (cg-RX-API-DMAC7.html)
PL (1) PL3478693T3 (cg-RX-API-DMAC7.html)
PT (1) PT3478693T (cg-RX-API-DMAC7.html)
SA (1) SA518400742B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201811549UA (cg-RX-API-DMAC7.html)
UA (1) UA124464C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018005662A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808327B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
CN117398398A (zh) 2017-03-06 2024-01-16 云顶新耀新加坡有限公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
WO2019204419A1 (en) * 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
SG11202105505TA (en) * 2018-11-29 2021-06-29 Venatorx Pharmaceuticals Inc Combination compositions comprising a beta-lactamase inhibitor and uses thereof
HUE072159T2 (hu) 2019-06-19 2025-10-28 Qpex Biopharma Inc Bórsav-származékok és terápiás alkalmazásuk
TW202123945A (zh) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 具有抗菌作用的醫藥組成物
CN114929715A (zh) * 2019-10-25 2022-08-19 住友制药株式会社 新型取代稠环型化合物
EP4121433A4 (en) * 2020-03-18 2024-06-19 Qpex Biopharma, Inc. BORIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
AU2021266715A1 (en) * 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
KR20230104117A (ko) * 2020-08-20 2023-07-07 파에노 테라퓨틱스 씨오., 엘티디. 붕산계 화합물
KR20230167077A (ko) * 2021-04-05 2023-12-07 큐펙스 바이오파마 인코포레이티드 세프티부텐 투여 요법
BR112023017203A2 (pt) 2021-04-13 2023-11-07 Tuojie Biotech Shanghai Co Ltd Derivado de ácido bórico que age como inibidor de beta-lactamase
CN113150022B (zh) * 2021-04-23 2022-12-06 四川大学 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途
KR20240115236A (ko) * 2021-10-19 2024-07-25 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 삼중 고리계 붕산 유도체 및 이의 제조 방법과 용도
CN119384424A (zh) * 2022-02-18 2025-01-28 辉诺生物医药科技(杭州)有限公司 新的硼酸类化合物的晶型及其制备方法
CN114716465B (zh) * 2022-05-06 2024-05-24 上海中医药大学 一种双环硼酸酯类化合物的制备方法及其应用
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) * 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) * 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
JP2002504122A (ja) 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー ベータラクタマーゼ阻害剤及びその使用方法
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
IL148818A0 (en) 1999-09-25 2002-09-12 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b
CA2388077A1 (en) 1999-10-28 2001-05-03 James M. Balkovec Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (en) 2000-09-12 2002-03-21 Shoichet Brian K β-LACTAM ANALOGS AND USES THEREFOR
AU1261402A (en) 2000-09-14 2002-03-26 Naeja Pharmaceutical Inc 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
EP1550657A4 (en) 2002-09-11 2009-12-30 Kureha Corp AMINO COMPOUNDS AND THEIR USE
EP3412696A1 (en) 2002-10-30 2018-12-12 Sumitomo Chemical Company, Limited High-molecular compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
MXPA05006798A (es) 2002-12-20 2006-03-09 Migenix Corp Ligandos de adenina nucleotido translocasa (ant) y composiciones y metodos relacionados a estos.
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
ES2288270T3 (es) 2003-10-10 2008-01-01 Pfizer Products Incorporated 2h-(1,2,4)triazolo(4,3-a)pirazinas sustituidas como inhibidores de gsk-3.
BRPI0416444B8 (pt) * 2003-11-12 2021-05-25 Chiesi Farm Spa composto de ácido borônico heterocíclico, composição farmacêutica, e, combinação farmacêutica compreendendo o mesmo
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
KR101337045B1 (ko) 2005-02-16 2013-12-05 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
CA2680693A1 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
DK2484680T3 (da) 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
KR20150013941A (ko) 2006-02-16 2015-02-05 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
WO2008039420A2 (en) 2006-09-27 2008-04-03 Merck & Co., Inc. Novel inhibitors of beta-lactamase
BRPI0809147A2 (pt) 2007-03-23 2014-08-26 Basilea Pharmaceutica Ag Medicamentos combinados para tratamento de infecções bacterianas
CA2694068C (en) * 2007-07-23 2016-08-30 The Board Of Trustees Of The University Of Illinois System for controlling the reactivity of boronic acids
JP5298129B2 (ja) * 2007-09-06 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化因子
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
AU2008321443A1 (en) 2007-11-13 2009-05-22 Novartis Ag Beta-lactamase inhibitors
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
ME02089B (me) 2008-01-18 2014-04-30 Merck Sharp & Dohme Inhibitori beta-laktamaze
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2273882A4 (en) 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
EP2406233B1 (en) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
JP2012529511A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
RU2012107163A (ru) 2009-07-28 2013-09-10 Анакор Фармасьютикалз, Инк. Тризамещенные борсодержащие молекулы
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
JP5909239B2 (ja) 2010-10-26 2016-04-26 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102320960A (zh) 2011-08-02 2012-01-18 安徽东健化工科技有限公司 一种6-氟水杨酸的制备方法
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
CN104321060B (zh) 2011-12-22 2018-08-07 阿雷斯贸易股份有限公司 α-氨基硼酸衍生物,选择性免疫蛋白酶体抑制剂
CA2862710A1 (en) 2012-01-09 2013-07-18 University Of Tromso Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
SG11201506875YA (en) 2013-03-15 2015-09-29 Intrexon Corp Boron-containing diacylhydrazines
HRP20191932T1 (hr) 2014-05-05 2020-01-24 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli i njihove uporabe
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016116892A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Antibacterial compositions
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3285776B1 (en) 2015-04-24 2022-12-21 Melinta Therapeutics, Inc. Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2017295866A1 (en) 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
PT3512851T (pt) 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
WO2019093450A1 (ja) 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
SG11202105505TA (en) 2018-11-29 2021-06-29 Venatorx Pharmaceuticals Inc Combination compositions comprising a beta-lactamase inhibitor and uses thereof
HUE072159T2 (hu) 2019-06-19 2025-10-28 Qpex Biopharma Inc Bórsav-származékok és terápiás alkalmazásuk
JP7673052B2 (ja) 2019-08-29 2025-05-08 アリクサ ファーマシューティカルズ、インコーポレイテッド 細菌感染症を処置するためのベータラクタム抗生物質およびアビバクタム誘導体の経口投与される組合せ

Similar Documents

Publication Publication Date Title
JP2019527196A5 (cg-RX-API-DMAC7.html)
RU2013104951A (ru) Циклические бороновые кислотно-эфирные производные и их использование в терапии
JP2023159197A5 (cg-RX-API-DMAC7.html)
US9687497B1 (en) Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2016146581A (ru) Макроциклические антибиотики широкого спектра действия
US10561675B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP2022137011A5 (cg-RX-API-DMAC7.html)
US9241947B2 (en) Boronic acid derivatives and therapeutic uses thereof
CA2982911C (en) Methods of treating bacterial infections
JP2016501864A5 (cg-RX-API-DMAC7.html)
US20200093814A1 (en) Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
JP2017517567A5 (cg-RX-API-DMAC7.html)
WO2013033461A1 (en) Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP2015521617A5 (cg-RX-API-DMAC7.html)
TW202005970A (zh) β-內醯胺化合物及丙磺舒之組合及其用途
JP7436206B2 (ja) 細菌感染症を処置する方法
JP2020507564A5 (cg-RX-API-DMAC7.html)
BRPI0612447A2 (pt) composição antibiótica de dose fixa, processo para a preparação de um produto de combinação antibiótica de dose fixa, processo para a preparação de uma injeção lìquida e usos de pó seco para injeção e injeção lìquida
JPWO2019204419A5 (cg-RX-API-DMAC7.html)
RU2018143900A (ru) Производные бороновой кислоты и их терапевтические применения
JP2023518418A (ja) ボロン酸誘導体およびその治療的使用
JPWO2021188700A5 (cg-RX-API-DMAC7.html)
JPWO2020033359A5 (cg-RX-API-DMAC7.html)
FI89454B (fi) Foerfarande foer framstaellning av ett lyofiliserat antibakteriellt preparat
NZ790559B2 (en) Macrocyclic broad spectrum antibiotics